{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:23:53Z","timestamp":1792416233956,"version":"4.4.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Private Universit\u00e4t Witten\/Herdecke gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Drug-induced interstitial lung disease (ILD) is a potentially severe pulmonary complication associated with various immunomodulatory and antineoplastic agents. Despite increasing recognition, comparative disproportionality data across drug classes remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS, 2004\u20132024). Twelve agents with known or suspected associations with ILD were selected. For each drug, the total number of adverse events and ILD reports were extracted. The proportional reporting ratio and reporting odds ratios (RORs) with 95% confidence intervals (CIs) were calculated to assess disproportionality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Methotrexate and rituximab accounted for the highest number of ILD reports. Amiodarone hydrochloride showed the highest proportion of ILD among its adverse events (9.4%) and the strongest disproportionality signal (ROR\u2009=\u20097.11; 95% CI: 6.79\u20137.45). Elevated RORs were also noted for leflunomide (3.05), tocilizumab (1.94), pembrolizumab (1.89), and methotrexate (1.90). In contrast, TNF-\u03b1 inhibitors such as adalimumab (ROR\u2009=\u20090.29) and etanercept (ROR\u2009=\u20090.34) were associated with lower disproportionality signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Significant variation in ILD signal strength was observed across drug classes. Amiodarone and leflunomide showed disproportionately strong ILD signals, while TNF-\u03b1 inhibitors demonstrated lower reporting frequencies. These findings underscore the need for ongoing pharmacovigilance when using agents with potential pulmonary toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-025-00468-9","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T17:34:34Z","timestamp":1752687274000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Drug-induced interstitial lung disease: a pharmacovigilance study of twelve immunomodulatory and antineoplastic agents"],"prefix":"10.1186","volume":"11","author":[{"given":"Josef","family":"Yayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"issue":"19","key":"468_CR1","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra1705751","volume":"378","author":"DJ Lederer","year":"2018","unstructured":"Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378(19):1811\u201323.","journal-title":"N Engl J Med"},{"issue":"7","key":"468_CR2","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796\u2013803.","journal-title":"Int J Med Sci"},{"issue":"9","key":"468_CR3","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1093\/rheumatology\/keab304","volume":"60","author":"AA Sherbini","year":"2021","unstructured":"Sherbini AA, Sharma SD, Gwinnutt JM, Hyrich KL, Verstappen SMM. Prevalence and predictors of adverse events with methotrexate mono- and combination-therapy for rheumatoid arthritis: a systematic review. Rheumatology (Oxford). 2021;60(9):4001\u201317. https:\/\/doi.org\/10.1093\/rheumatology\/keab304. PMID: 33909898; PMCID: PMC8410011.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"468_CR4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1034\/j.1399-3003.2000.15b25.x","volume":"15","author":"S Imokawa","year":"2000","unstructured":"Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J. 2000;15(2):373\u201381.","journal-title":"Eur Respir J"},{"issue":"5","key":"468_CR5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3899\/jrheum.150674","volume":"43","author":"R Conway","year":"2016","unstructured":"Conway R, Low C, Coughlan RJ, O\u2019Donnell MJ, Carey JJ. Leflunomide use and risk of lung disease in rheumatoid arthritis: A systematic literature review and metaanalysis of randomized controlled trials. J Rheumatol. 2016;43(5):855\u201360. https:\/\/doi.org\/10.3899\/jrheum.150674. Epub 2016 Mar 15. PMID: 26980577.","journal-title":"J Rheumatol"},{"issue":"12","key":"468_CR6","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","volume":"2","author":"M Nishino","year":"2016","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(12):1607\u201316.","journal-title":"JAMA Oncol"},{"key":"468_CR7","doi-asserted-by":"publisher","unstructured":"Manfredi A, Cassone G, Furini F, Gremese E, Venerito V, Atzeni F, Arrigoni E, Della Casa G, Cerri S, Govoni M, Petricca L, Iannone F, Salvarani C, Sebastiani M. Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. Intern Med J. 2020;50(9):1085\u20131090. https:\/\/doi.org\/10.1111\/imj.14670. PMID: 31661185.","DOI":"10.1111\/imj.14670"},{"issue":"2","key":"468_CR8","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","volume":"41","author":"R Perez-Alvarez","year":"2011","unstructured":"Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011;41(2):256\u201364.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"468_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/MD.0b013e318190f170","volume":"87","author":"M Ramos-Casals","year":"2008","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Mu\u00f1oz S, Soto MJ. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Med (Baltim). 2008;87(6):345\u201364.","journal-title":"Med (Baltim)"},{"issue":"5","key":"468_CR10","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1378\/chest.93.5.1067","volume":"93","author":"WJ Martin","year":"1988","unstructured":"Martin WJ 2nd, Rosenow. EC 3rd. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I). Chest. 1988;93(5):1067\u201375.","journal-title":"Chest"},{"issue":"2","key":"468_CR11","first-page":"43","volume":"16","author":"N Wolkove","year":"2009","unstructured":"Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J. 2009;16(2):43\u20138.","journal-title":"Can Respir J"},{"issue":"2","key":"468_CR12","doi-asserted-by":"publisher","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","volume":"50","author":"M Delaunay","year":"2017","unstructured":"Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017;50(2):1700050.","journal-title":"Eur Respir J"},{"issue":"10","key":"468_CR13","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/jcm7100356","volume":"7","author":"S Skeoch","year":"2018","unstructured":"Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, Hayton C, et al. Drug-Induced interstitial lung disease: A systematic review. J Clin Med. 2018;7(10):356.","journal-title":"J Clin Med"},{"issue":"4","key":"468_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1159\/000079633","volume":"71","author":"P Camus","year":"2004","unstructured":"Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration. 2004;71(4):301\u201326.","journal-title":"Respiration"},{"issue":"1","key":"468_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0272-5231(03)00138-2","volume":"25","author":"DB Flieder","year":"2004","unstructured":"Flieder DB, Travis WD. Pathologic characteristics of drug-induced lung disease. Clin Chest Med. 2004;25(1):37\u201345.","journal-title":"Clin Chest Med"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00468-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-025-00468-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00468-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:39:01Z","timestamp":1781613541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-025-00468-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["468"],"URL":"https:\/\/doi.org\/10.1186\/s40780-025-00468-9","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The study used publicly available anonymized data from the FAERS database and does not involve human participants or personal data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}